Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment

Mitra Dolatkhah ^1,2, Yadollah Omidi ^1,2 *

Cited by CrossRef: 9

1- Kast R. Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation. Annales Pharmaceutiques Françaises. 2021;79(5):481 [Crossref]

2- Buyse C, Joudiou N, Warscotte A, Richiardone E, Mignion L, Corbet C, Gallez B. Evaluation of Syrosingopine, an MCT Inhibitor, as Potential Modulator of Tumor Metabolism and Extracellular Acidification. Metabolites. 2022;12(6):557 [Crossref]

3- Hladkykh F, Kulinich Н, Zolotarova T. New approaches to radio- and chemosensitization using proton pump inhibitors through the lens of tumor cell microenvironment patterns. УРОЖ. 2023;31(2):230 [Crossref]

4- Xiang A, Chen X, Xu P, Shao S, Shen Y. Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma. BMC Urol. 2022;22(1) [Crossref]

5- Omidi Y, Mobasher M, Castejon A, Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. Journal of Drug Targeting. 2022;30(7):687 [Crossref]

6- Dolatkhah M, Hashemzadeh N, Barar J, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidian H, Omidi Y. Stimuli-Responsive Graphene Oxide and Methotrexate-Loaded Magnetic Nanoparticles for Breast Cancer-Targeted Therapy. Nanomedicine (Lond). 2021;16(24):2155 [Crossref]

7- Altei W, Pachane B, Souza C, Marques M, Selistre-de-Araújo H. New insights into the discovery of drugs for triple-negative breast cancer metastasis. Expert Opinion on Drug Discovery. 2022;17(4):365 [Crossref]

8- Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y, Barar J. Recent advances in breast cancer immunotherapy: The promising impact of nanomedicines. Life Sciences. 2021;271:119110 [Crossref]

9- Zhang P, Sun Y, Shi L, Sun D, Wang L, Feng D, Ding C. Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of bladder cancer by activating PPARγ/PTEN/AKT pathway. Tissue and Cell. 2023;82:102048 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons